US 11,851,442 B2
Tricyclic fused thiophene derivatives as JAK inhibitors
Yun-Long Li, Chadds Ford, PA (US); Wenyu Zhu, Media, PA (US); Song Mei, Wilmington, DE (US); and Joseph Glenn, Mount Royal, NJ (US)
Assigned to Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed on Aug. 12, 2021, as Appl. No. 17/400,861.
Application 17/400,861 is a continuation of application No. 16/454,830, filed on Jun. 27, 2019, granted, now 11,161,855.
Application 16/454,830 is a continuation of application No. 15/874,140, filed on Jan. 18, 2018, granted, now 10,370,387, issued on Aug. 6, 2019.
Application 15/874,140 is a continuation of application No. 14/873,078, filed on Oct. 1, 2015, granted, now 9,908,895, issued on Mar. 6, 2018.
Application 14/873,078 is a continuation of application No. 14/068,796, filed on Oct. 31, 2013, granted, now 9,181,271, issued on Nov. 10, 2015.
Claims priority of provisional application 61/783,850, filed on Mar. 14, 2013.
Claims priority of provisional application 61/721,308, filed on Nov. 1, 2012.
Prior Publication US 2021/0387998 A1, Dec. 16, 2021
Int. Cl. C07D 495/14 (2006.01); C07D 495/12 (2006.01); A61K 31/437 (2006.01)
CPC C07D 495/14 (2013.01) [A61K 31/437 (2013.01); C07D 495/12 (2013.01)] 12 Claims
 
1. A method of ameliorating or inhibiting a myeloproliferative disorder in a patient, comprising administering to said patient a compound, which is ((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrile, or a pharmaceutically acceptable salt thereof, wherein the myeloproliferative disorder is polycythemia vera (PV), myelofibrosis, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (Post-PV MF), post-essential thrombocythemia myelofibrosis (Post-ET MF), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).